Funding traction Endovascular Engineering has secured a significant Series B raise of 42 million, signaling strong investor confidence and potential for accelerated near-term commercialization of their Hēlo thrombectomy platform, creating opportunity for collaboration, pilots, and early adopter programs with healthcare providers and distributors.

Clinical momentum With ENGULF Study positive initial results for the Hēlo Thrombectomy System, there is evidence of clinical efficacy that can be leveraged for KOL engagement, targeted hospital partnerships, and accelerated payor discussions to support adoption of their venous thromboembolism solution.

Leadership signal Change in leadership with a new CEO in 2024 indicates a strategic shift toward scale and market execution, presenting an opening for executive-level alignment, strategic alliances, and joint go-to-market planning with potential customers and large healthcare systems.

Market fit Focused on venous thromboembolism and clot removal technologies, E2 sits at the intersection of high-need vascular care and interventional devices, offering sales opportunities with hospitals, vascular centers, and specialized distributors seeking innovative thrombectomy solutions.

Financial runway With reported revenue in the multiple tens of millions and substantial total funding, there is a credible path to expansion, enabling sales teams to plan multi-year deployments, phased deployments in high-volume centers, and bundled offerings for early adopters.